Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. Pfizer’s decision sent ...

Pfizer made one thing clear this week: It's officially back in the obesity race.

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well with its antibody-drug conjugates (ADCs). Ivonescimab remains the frontrunner ...

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Investors once speculated that Pfizer might consider acquiring Viking. Weight loss drugs have represented an enormous growth area for biotech and pharma companies over the past couple of years. Pharma ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Pfizer-backed biotech landed ...

These players are vying for positions in the billion-dollar weight loss drug market. Demand for weight loss drugs is soaring, suggesting there's room for more than one winner. 10 stocks we like better ...